2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France

被引：20

作者：

Penault-Llorca, Frederique ^{[1
]}

Vincent-Salomon, Anne ^{[1
]}

MacGrogan, Gaetan ^{[1
]}

Roger, Pascal ^{[1
]}

Treilleux, Isabelle ^{[1
]}

Valent, Alexander ^{[1
]}

Mathieu, Marie-Christine ^{[1
]}

Antoine, Martine ^{[1
]}

Becette, Veronique ^{[1
]}

Bor, Catherine ^{[1
]}

Brabencova, Eva ^{[1
]}

Charafe-Jauffret, Emmanuelle ^{[1
]}

Chenard, Marie-Pierre ^{[1
]}

Dauplat, Marie-Melanie ^{[1
]}

Delree, Paul ^{[1
]}

Devouassoux, Mojgan ^{[1
]}

Fiche, Maryse ^{[1
]}

Fondrevelle, Marie-Eve ^{[1
]}

Fridman, Viviana ^{[1
]}

Garbar, Christian ^{[1
]}

Genin, Pascal ^{[1
]}

Ghnassia, Jean-Pierre ^{[1
]}

Haudebourg, Juliette ^{[1
]}

Laberge-Le Couteulx, Sophie ^{[1
]}

Loussouarn, Delphine ^{[1
]}

Maran-Gonzalez, Aurelie ^{[1
]}

Marcy, Myriam ^{[1
]}

Michenet, Patrick ^{[1
]}

Poulet, Bruno ^{[1
]}

Sagan, Christine ^{[1
]}

Trassard, Martine ^{[1
]}

Verriele, Veronique ^{[1
]}

Arnould, Laurent ^{[1
]}

Lacroix-Triki, Magali ^{[1
]}

机构：

[1] Unicancer, Grp Etud Facteurs Pronost Immunohistochim Canc Se, F-75654 Paris 13, France

来源：

ANNALES DE PATHOLOGIE | 2014年 / 34卷 / 05期

关键词：

HER2; Breast cancer; Immunohistochemistry; In situ hybridization; Guidelines; IN-SITU HYBRIDIZATION; CORE-NEEDLE BIOPSIES; GENE AMPLIFICATION; IMMUNOHISTOCHEMISTRY; FISH;

D O I：

10.1016/j.annpat.2014.08.018

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

International guidelines on HER2 determination in breast cancer have just been updated by the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP), on the basis of more than ten-year practice, results of clinical trials and concordance studies. The GEFPICS group, composed of expert pathologists in breast cancer, herein presents these recommendations, adapted to the French routine practice. These guidelines highlight the possible diagnosis difficulties with regards to HER2 status determination, such as intra-tumor heterogeneity, special histological subtypes and biomarker re-evaluation during metastatic relapse. Pre-analytical issues and updated scoring criteria (especially for equivocal cases) are detailed, in order to decrease the occurrence of false negative cases. In the era of personalized medicine, pathologists are more than ever involved in the quality of oncotheranostic biomarker evaluation. (C) 2014 Elsevier Masson SAS. All rights reserved.

引用

页码：352 / 365

页数：14

共 50 条

[1] Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France
Penault-Llorca, Frederique
Vincent-Salomon, Anne
Bellocq, Jean-Pierre
Matthieu, Marie-Christine
Grogan, Gaetan-Mac
Treilleux, Isabelle
Ettore, Francette
Laberge-Le Couteulx, Sophie
Sigal, Brigitte
Couturier, Jerome
Lacroix-Triki, Magali
Antoine, Martine
Balaton, Andre
Baranzelli, Marie-Christine
Becette, Valerie
Blanc-Fournier, Cecile
Bibeau, Frederic
Brabencova, Eva
Croce, Sabrina
Fridman, Viviana
Genin, Pascal
Ghnassia, Jean-Pierre
Jacquemier, Jocelyne
Poulet, Bruno
Roger, Pascal
Sagan, Christine
Tas, Patrick
Trassard, Martine
Verriele, Veronique
Arnould, Laurent
[J]. ANNALES DE PATHOLOGIE, 2010, 30 (05) : 357 - 373
[2] UPDATE OF THE RECOMMENDATIONS FOR HER2 STATUS DETERMINATION IN BREAST CANCERS: ASCO/CAP 2013 AND GEFPICS 2014.
Chahdi, H.
Allaoui, M.
Boudhas, A.
Tbouda, M.
El Ochi, M. R.
Damiri, A.
Al Bouzidi, A.
Oukabli, M.
[J]. JOURNAL OF MEDICAL AND SURGICAL RESEARCH, 2016, 3 (02): : 265 - 266
[3] 2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France
Franchet, Camille
Djerroudi, Lounes
Maran-Gonzalez, Aurelie
Abramovici, Olivia
Antoine, Martine
Becette, Veronique
Berghian, Anca
Blanc-Fournier, Cecile
Brabencova, Eva
Charafe-Jauffret, Emmanuelle
Chenard, Marie-Pierre
Dauplat, Marie-Melanie
Delree, Paul
Duprez-Paumier, Raphaelle
Fleury, Clemence
Ghnassia, Jean-Pierre
Haudebourg, Juliette
Leroux, Agnes
MacGrogan, Gaetan
Mathieu, Marie-Christine
Michenet, Patrick
Penault-Llorca, Frederique
Poulet, Bruno
Robin, Yves Marie
Roger, Pascal
Russ, Elisabeth
Tixier, Lucie
Treilleux, Isabelle
Valent, Alexander
Verriele, Veronique
Vincent-Salomon, Anne
Arnould, Laurent
Lacroix-Triki, Magali
[J]. ANNALES DE PATHOLOGIE, 2021, 41 (06) : 507 - 520
[4] HER2 status and disparities in luminal breast cancers
Holowatyj, Andreana N.
Ruterbusch, Julie J.
Ratnam, Manohar
Gorski, David H.
Cote, Michele L.
[J]. CANCER MEDICINE, 2016, 5 (08): : 2109 - 2116
[5] UK recommendations for HER2 assessment in breast cancer: an update
Rakha, Emad A.
Tan, Puay Hoon
Quinn, Cecily
Provenzano, Elena
Shaaban, Abeer M.
Deb, Rahul
Callagy, Grace
Starczynski, Jane
Lee, Andrew H. S.
Ellis, Ian O.
Pinder, Sarah E.
[J]. JOURNAL OF CLINICAL PATHOLOGY, 2023, 76 (04) : 217 - 227
[6] Her2/neu status in bone metastases of breast cancers
Lörincz, T
Tóth, J
Szendröi, M
Tímár, J
[J]. PROCEEDINGS OF THE 2ND CONGRESS OF THE WORLD SOCIETY FOR BREAST HEALTH, 2003, : 35 - 38
[7] Update on HER2 testing for breast and upper gastrointestinal tract cancers
Ross, Jeffrey S.
[J]. BIOMARKERS IN MEDICINE, 2011, 5 (03) : 307 - 318
[8] Internal quality control on HER2 status determination in breast cancers: Experience of a cancer center
Ngo, Carine
Lae, Marick
Ratour, Julia
Hamel, Frederique
Taris, Corinne
Caly, Martial
Le Cunff, Annie
Reyal, Fabien
Kirova, Youlia
Pierga, Jean-Yves
Vincent-Salomon, Anne
[J]. BULLETIN DU CANCER, 2017, 104 (7-8) : 608 - 617
[9] HER2 Intermediate Breast Cancers
Jensen, Kristin C.
Nielsen, Torsten O.
Gilks, C. Blake
West, Robert B.
[J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2009, 33 (11) : 1739 - 1739
[10] HER2 Dual ISH Determination of HER2 Gene Status in Breast Cancer: Interobserver Reproducibility
Limbach, A. A. Lott
Downs-Kelly, E. P.
Papouchado, B. G.
Tubbs, R. R.
Lanigan, C.
Booth, C. N.
[J]. LABORATORY INVESTIGATION, 2012, 92 : 52A - 52A

← 1 2 3 4 5 →